Anti-CD194重组抗体|科研级 Mogamulizumab ( 莫格利组单抗 )-重组抗体试剂-泰克生物-酵母展示服务专家

Anti-CD194重组抗体|科研级 Mogamulizumab ( 莫格利组单抗 )

详细相关信息靶点背景信息实验方案&FAQ 相关产品推荐服务

询价与订购

姓名*
电话号码*
电子邮件*
产品名称*
描述*

Anti-CD194重组抗体|科研级 Mogamulizumab ( 莫格利组单抗 )

说明书联系我们

< >

详细相关信息

靶点背景信息

实验方案&FAQ

Catalog Number

TKYR1245

Alias

科研级 Mogamulizumab ( 莫格利组单抗 ), Anti-CD194 Recombinant Antibody, Research Grade Mogamulizumab

Molecular Name

Mogamulizumab

Size

1mg, 5mg

CAS Number

1159266-37-1

Isotype

IgG1 Kappa

Clonality

Monoclonal

Concentration

1mg/ml

Source

CHO Cells

Purity

≥95% as determined by SDS-PAGE

Buffer

Supplied in PBS, PH7.5

Target

CCR4/CD194[Homo sapiens]

Sequence

Please contact our sales representative to learn more information about this reagents.

Background

Mogamulizumab, sold under the brand name Poteligeo, is a humanized, afucosylated monoclonal antibody targeting CC chemokine receptor 4 (CCR4). The U.S. Food and Drug Administration (FDA) approved it in August 2018 for treatment of relapsed or refractory mycosis fungoides and Sézary disease. It was approved in Japan in 2012, for the treatment of relapsed or refractory CCR4+ adult T-cell leukemia/lymphoma (ATCLL) and in 2014, for relapsed or refractory CCR4+ cutaneous T cell lymphoma (CTCL).

Storage

该产品可在 2°C-8°C 下保存一个月，活性不会明显降低。在 -20°C 至 -80°C 下保存，可稳定保存十二个月。避免反复冻融,用冰袋运输。

NOTE

仅科研使用

靶点背景信息

实验方案&FAQ